ArticleERJ open research2025
Acute effects of 50 mg additive oral sildenafil on invasive exercise haemodynamics in pulmonary vascular disease.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of sildenafil on resting and exercise haemodynamics in hypoxia in patients with pulmonary vascular diseases: data from a randomised controlled trial.ERJ open research · 2026Article
- Cerebral, Muscle and Blood Oxygenation in Patients with Pulmonary Vascular Disease Whilst Breathing Normobaric Hypoxia vs. Normoxia Before and After Sildenafil: Data from a Randomised Controlled Trial.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Patients with precapillary pulmonary hypertension (PH) due to pulmonary vascular disease (PVD) have reduced exercise capacity, limiting daily activity and quality of life. Phospodiesterase-5 inhibitors, including sildenafil, are used to treat PVD. This study examined effects of sildenafil on pulmonary haemodynamics during exercise in PVD. Method: PVD patients diagnosed with pulmonary arterial hypertension (PAH) or chronic thromboembolic PH (CTEPH) underwent right heart catheterisation assessed at rest and during mild exercise. Main outcomes were mean pulmonary artery pressure (mPAP), cardiac output (CO) and the mPAP/CO slope before and ∼60 min after additive sildenafil (50 mg oral). Results: 22 PVD patients (14 PAH, 8 CTEPH, 9 women and 15 pretreated (9 combination therapy)) with a mean±sd age of 54±14 years, mPAP 39±10 mmHg, CO 4.7±1.5 L·min Conclusions: Patients with PVD, showed favourable acute pulmonary haemodynamic changes during exercise after additive sildenafil, indicated by a reduced mPAP and mPAP/CO slope. Sildenafil was generally well tolerated despite lower blood pressure. Further investigation is needed to determine if sildenafil as a "pill-in-the-pocket" strategy improves exercise capacity in PVD patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.